The Official Journal of the Turkish Society Of Clinical Microbiology and Infectious Diseases (KLİMİK)

Original Article

SARS-CoV-2 Infection may be Prevented with Cytochrome Inhibitors: Cobicistat and Ritonavir

İsmail Çelik
  • Department of Pharmaceutical Chemistry, Erciyes University School of Pharmacy, Erciyes University, Kütahya, Turkey
Ezgi Gülten
  • Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Turkey
Arzu Onay-Beşikci
  • Department of Pharmacology, Ankara University School of Pharmacy, Ankara, Turkey
Güle Çınar
  • Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Turkey
İrem Akdemir-Kalkan
  • Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Turkey
Gülgün Kılcıgil
  • Department of Pharmaceutical Chemistry, Ankara University School of Pharmacy, Ankara, Turkey
K. Osman Memikoğlu
  • Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Turkey
M. Serhat Birengel
  • Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Turkey
Alpay Azap
  • Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Turkey


Objective: Highly contagious character of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lack of specific drugs have led many scientists worldwide to re-evaluate the molecules currently in use for other diseases/viruses. Thus, high-throughput screening with docking studies has the rationale to identify potential therapeutics from existing drug molecules. Conflicting results of the studies, including SARS-CoV-2 and human immunodeficiency virus (HIV) coinfected population, suggested a possible preventive effect of antiretroviral regimens they have been receiving. 

Materials and Methods: Interactions between the widely used antiretroviral molecules, in particular; abacavir, cobicistat, dolutegravir, elvitegravir, emtricitabine, lamivudine, raltegravir, and tenofovir, and the main proteins on SARS-CoV-2 that may be targeted for SARS-CoV-2 infection were analyzed using molecular docking studies.  

Results: Analysis of the compounds strikingly revealed that not the antiretroviral drugs but cobicistat and ritonavir, the inhibitors of cytochrome P450, had strong interactions with the main protease active site and RNA polymerase on SARS-CoV-2, as well as the active site of angiotensin-converting–enzyme 2, the protein that enables the entry of the virus into human cells.  

Conclusion: Our results suggest cobicistat and ritonavir may be used to prevent SARS-CoV-2 infection. 

Keywords: antiretroviral therapy, cobicistat, ritonavir, SARS-CoV-2


Since its emergence in December 2019, 530,266,292 confirmed coronavirus disease 2019 (COVID-19) cases, including 6,299,364 deaths were reported as of June 7, 2022 (1). It’s widely accepted that in older age, comorbidities (hypertension, diabetes mellitus, obesity, chronic respiratory disease, chronic kidney disease, cardiovascular disease, malignancies) and immunosuppression significantly increase the risk of severe COVID-19 (2, 3).

Worldwide, 37.7 million people are infected with the human immunodeficiency virus (HIV) (4). Since early in the COVID-19 pandemic, there has been a growing interest in exploring the impact of COVID-19 among people living with HIV (PLWH). Although initial studies assessing the severity of COVID-19 among PLWH do not suggest poorer outcomes, recent findings showed a higher risk of morbidity and mortality, particularly in those with lower CD4 cell counts, unsuppressed HIV viremia and comorbidities mentioned above (5, 6). Still, it is debated whether PLWH have an increased risk of severe COVID-19, as the data come from cohort studies performed with unmatched populations. Despite the existing debate, World Health Organization (WHO) Global Clinical Platform for COVID-19 announced HIV infection as an independent risk factor for severe COVID-19 (7). The susceptibility of PLWH to SARS-CoV-2 infection has also been debated. The incidence of COVID-19 among PLWH ranges between 0.3-5.7% (5, 8). Current data revealed that SARS-CoV-2 infection rates among PLWH are not higher than their HIV-negative counterparts (8, 9). It was speculated that PLWH have a lower risk of SARS-CoV-2 infection rates in terms of preventive effects of antiretroviral therapy (ART) against COVID-19 (8). In two cohort studies from Spain and South Africa, tenofovir disoproxil fumarate use was linked with lower SARS-CoV-2 infection rates (8,10). In a letter by Joob et al., where the authors shared their observation in Thailand within a high prevalence area of HIV infection, authors reported that HIV-infected patients on antiretroviral treatment (lopinavir/ritonavir) have not been infected with SARS-CoV-2 and concluded that antiretroviral treatment might be a protective factor for PLWH (11). 

On the other hand, Ayerdi et al., reported higher SARS-CoV-2 seroprevalence in tenofovir disoproxil fumarate/emtricitabine users compared to the control group (12). Similarly, the Prevenir ANRS study group couldn’t find any evidence of a preventive effect of tenofovir disoproxil fumarate/emtricitabine against SARS-CoV-2 infection (13). Also, results of the studies investigating the therapeutic role of lopinavir/ritonavir and darunavir/cobicistat in SARS-CoV-2 infection were not in favor of using these antiretroviral drug combinations (14-17). Unfortunately, there is a lack of population-based studies assessing the COVID-19 susceptibility of PLWH who receive different antiretroviral molecules. Consequently, whether various antiretroviral drugs have preventive effect against SARS-CoV-2 infection or PLWH under ART have a milder course of COVID-19 still remains unanswered. 

Controversial results of the studies mentioned above led us to analyze the widely used antiretroviral molecules, in particular; abacavir, cobicistat, dolutegravir, elvitegravir, emtricitabine, lamivudine, raltegravir, and tenofovir, for possible interactions with SARS-CoV-2 as well as angiotensin-converting enzyme 2 (ACE2), the protein that participates in the entry of SARS-CoV-2 into human cells.  

Materials and Methods

Molecular Docking 

Molecular docking studies were performed in Schrödinger Maestro version 11.5 software (Schrödinger, LLC, New York, USA) in four stages: protein preparation, ligand preparation, grid determination, and docking. Firstly, the crystal structure of the SARS-CoV-2 chimeric receptor-binding domain complexed with its receptor human ACE2 (protein data bank [PDB]: 6VW1), SARS-CoV-2 spike ectodomain structure (open state) (PDB: 6VYB), structure of the SARS-CoV-2 spike glycoprotein (closed state) (PDB: 6VXX), structure of the post-fusion core of SARS-CoV-2 S2 subunit (PDB: 6VXX and PDB: 6LXT), structure of SARS-CoV-2 RNA-dependent RNA polymerase (PDB: 6M71) and structure of SARS-CoV-2 main protease (PDB: 6LU7) were downloaded from RCSB Protein Data Bank (PDB) ( and prepared in three steps: preprocess, review & modify and refinement by using “Protein Preparation Wizard” module (18-22). The energy of the protein structures was minimized using OPLS3 force field. In the second stage, cobicistat, lopinavir, ritonavir, emtricitabine, lamivudine, abacavir, dolutegravir, elvitegravir, raltegravir, and tenofovir were downloaded in 3D SDF format from  National Library of Medicine (NIH) PubChem ( and prepared using OPLS3 force field and ionization which generated possible states at target pH: 7+/-2 with Epik (Schrödinger, LLC, New York, USA) by using “LigPrep”module. In the third stage, binding site determination of SARS-CoV-2 main protease (PDB: 6LU7) was run by clicking any atom of the ligand, and the grid box was created 20x20x20 Å size. The active site of other protein structures, whose protein-ligand complex structure has not been obtained yet and whose active site is not fully known, were determined using the “Binding Site Detection” module. All possible active sites were determined and adjusted to 20x20x20 Å using the “Receptor Grid Generation” module. At the last stage, molecular docking was performed in SP (standard precision) and flexible ligand options using the “Glide Ligand Docking” module. Docking, Glide and Glide emodel scores were calculated and evaluated. Extra precisions (XP) docking was performed on antiretroviral drug molecules with high SP docking scores. Molecular mechanics with generalized born surface area (MM-GBSA) values were calculated using the ‘Prime’ module to improve the scores of molecules with high XP docking results. Finally, possible 2D and 3D interactions between ligand and protein were identified. 


Figure 1. Cobicistat interaction with angiotensin-converting enzyme 2 (ACE-2).

Two possible active sites have been identified on “A” chain of ACE2 by the “Binding Site Detection” module. XP docking for site 2 (x: 99.52, y: 10.48, z: 162.85) revealed the strongest interaction with cobicistat with a Glide score of -6.988 and Glide emodel score of -98.644. Ritonavir showed the second highest interaction with -6.210 and -98.377 Glide and Glide emodel scores, respectively. Compared to these scores, interactions of other molecules with active site 2 were quite low. Cobicistat and ACE2 active site had strong chemical interactions with hydrogen bonds, π–π stacking and hydrophobic interactions (Figure 1).  

Figure 2. Cobicistat interaction with SARS-CoV-2 main protease.

The active site of SARS-CoV-2 is known, and many protein-ligand complexes exist in PDB. Re-docking after removal of the ligand from the main protease-ligand complex 6LU7 revealed a Glide score of -8.110 and a Glide emodel score of -99.463. Cobicistat had the highest interaction with the main protease active site with a -7.763 Glide score, a -124.242 Glide emodel score and a MM-GBSA value of -105.13. Ritonavir (Glide score: -6.858, Glide emodel score: -89.094, MM-GBSA value: -100.77) and lopinavir (Glide score: -6.867, Glide emodel score: -86.508, MM-GBSA value: -71.35) also interacted with this site while none of the other compounds interacted with the active site of SARS-CoV-2. Chemical interactions between cobicistat and SARS-CoV-2 main protease active site were through hydrogen bonds and hydrophobic interactions (Figure 2).

Figure 3. Cobicistat interaction with RNA polymerase.

By using remdesivir, a known inhibitor of RNA polymerase (PDB code 6M71), binding site 2 was confirmed to be the active region of this enzyme. Yet, docking analyses were performed for all five binding sites on RNA polymerase. Again, SP docking showed that cobicistat has the strongest interaction with binding site 2 (XP docking score: -6.012, Glide score: – 7.639, Glide emodel score: -91.419, MM-GBSA value: -108.03). Although with higher energies, ritonavir (Glide score: -5.973, Glide emodel score: -76.862, MM-GBSA value: -78.13) also interacted with this site as while no interaction was found with other compounds. Chemical interactions between cobicistat and RNA polymerase binding site 2 were through one hydrogen bond and hydrophobic interactions (Figure 3).

In the docking procedure performed in this study, remdesivir, an RNA polymerase inhibitor, showed the highest interaction in RNA polymerase binding site 2, and other compounds other than cobicistat and ritonavir did not interact. In addition, obtaining the correct pose by re-docking the ligand to the main protease active site showed the reliability of our docking studies. 

None of the drugs interacted with spike protein S1 (PDB: 6VW1_E chain), the post-fusion core of SARS-CoV-2 S2 subunit (PDB: 6LXT), SARS-CoV-2 spike glycoprotein (closed state, PDB: 6VXX) or SARS-CoV-2 spike ectodomain structure (open state, PDB: 6VYB). The results of molecular docking studies are provided as supplementary material (Supplementary Material -1). 


Finding new drugs via traditional methods is a time-consuming and expensive process. Therefore, molecular docking appears to be a useful way to find candidates from an existing library (23). To the best of our knowledge, the antiviral activity of cobicistat and ritonavir against SARS-CoV-2 has not been explored in the literature. Instead, both molecules act as pharmacokinetic enhancers by increasing the systemic exposure of co-administered antiviral agents. The present study indicated that compared to other molecules analyzed, cobicistat had the strongest interaction with SARS-CoV-2 RNA polymerase and main protease, which may suggest a rather unexpected inhibitory/antiviral effect. Ritonavir, a chemically similar antiviral agent, also interacted with these proteins with higher energy. In line with our findings, in several molecular screening studies, cobicistat and ritonavir have been proposed to be SARS-CoV-2 main protease inhibitors (24-26). 

Although observational studies have indicated a potential benefit of lopinavir/ritonavir in the treatment of COVID-19 patients, RECOVERY, SOLIDARITY, and CORIST trials failed to demonstrate the clinical benefit of lopinavir/ritonavir treatment beyond standard care (14-16). Similarly, the darunavir/cobicistat combination was not found to be useful in the treatment of SARS-CoV-2 infected patients. Indeed, the authors mentioned that darunavir/cobicistat therapy was associated with an increased risk of death in two observational cohort studies, probably due to drug-drug interactions (16, 17). However, there is still a lack of randomized controlled trials assessing the effect of darunavir/cobicistat treatment among COVID-19 patients. 

Pharmacologically, ACE2 is accepted as the receptor for SARS-CoV-2. Therefore, a compound that blocks ACE2 is expected to prevent SARS-CoV-2 entry into human cells. Our unexpected finding that cobicistat and ritonavir interact with ACE2 with low energy indicates that these molecules may be preventing the entry of SARS-CoV-2 by occupying its receptor. Prashantha et al., showed that both drugs have good affinity toward spike protein (27). Pfizer’s Paxlovid study, a co-packaged combination of nirmatrelvir and ritonavir, has been found to be 89% effective in patients at risk of serious COVID-19 (28). Although the scientific reports are awaited, one of the other main goals of the Paxlovid study is to assess the preventive effect of this combination on the household contacts of SARS-CoV-2 infected patients. According to our study results, ritonavir may contribute to the preventive effect of nirmatrelvir. In literature search, we could not find any clinical studies investigating cobicistat’s preventive effect against SARS-CoV-2 infection. 

Our results suggest that both cobicistat and ritonavir may have preventive and therapeutic potential in SARS-CoV-2 infection. However, albeit indirect, the easiest way to determine whether this effect exists or not appears to be a long-term study in PLWH under antiretroviral regimens including these molecules. 

Ethical Approval: N/A.

Informed Consent: N/A.

Peer-review: Externally peer-reviewed

Author Contributions: Concept – E.G., İ.Ç.; Design – E.G., İ.Ç., A.O.B., GAK, A.A., İ.A.K., G.Ç., M.S.B., K.O.M.; Supervision – A.O.B., GAK, A.A., M.S.B., K.O.M.; Fundings – İ.Ç., A.O.B., GAK; Data Collection and/or Processing – E.G., İ.Ç., A.O.B., GAK; Analysis and/or Interpretation – İ.Ç.; E.G., A.O.B., G.Ç., İ.A.K., G.K., K.O.M., M.S.B., A.A.; Literature Review – İ.Ç.; E.G., A.O.B., G.Ç., İ.A.K., G.K., K.O.M., M.S.B., A.A.; Writer – A.A., A.O.B., E.G.; Critical Reviews – İ.Ç.; E.G., A.O.B., G.Ç., İ.A.K., G.K., K.O.M., M.S.B., A.A.

Conflict of Interest: The authors declare no conflict of interest.

Financial Disclosure: There are no financial conflicts of interest to disclose.

Scientific Presentation: The present study was presented during KLİMİK COVID-19 Symposium as an oral presentation in Turkey on September 10-12, 2021.

Show References


  1. Coronavirus (COVID-19) Dashboard [Internet]. Genava: World Health Organization (WHO). (cited March 1, 2022). Available from:
  2. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9. Erratum in: JAMA. 2020;323(20):2098. [CrossRef]
  3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. Erratum in: Lancet. 2020;395(10229):1038. Erratum in: Lancet. 2020;395(10229):1038. [CrossRef]
  4. UNAIDS Data 2021[Internet]. Geneva: UNAIDS. (cited March 1, 2022). Available from:
  5. Nomah DK, Reyes-Urueña J, Llibre JM, Ambrosioni J, Ganem FS, Miró JM, et al. HIV and SARS-CoV-2 Co-infection: Epidemiological, clinical features, and future implications for clinical care and public health for people living with HIV (PLWH) and HIV most-at-risk groups. Curr HIV/AIDS Rep. 2021;18(6):518-26. [CrossRef]
  6. Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, Chinchilli VM, Nunez JJ, et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021;11(1):6283. [CrossRef]
  7. Bertagnolio S, Thwin S, Silva R, Ford N, Baggaley R, Vitoria M, et al. Clinical characteristics and prognostic factors in people living with HIV hospitalized with COVID-19: findings from the WHO Global Clinical Platform [Abstract]. In: Abstracts of 11th International AIDS Society (IAS) Conference on HIV Science (July 18-21, 2021).
  8. Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al; The Spanish HIV/COVID-19 Collaboration. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy : A cohort study. Ann Intern Med. 2020;173(7):536-41. [CrossRef]
  9. Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021;4(2):e2037069. [CrossRef]
  10. Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa. Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis. 2021;73(7):e2005-e15. Erratum in: Clin Infect Dis. 2022;74(7):1321. [CrossRef]
  11. Joob B, Wiwanitkit V. SARS-CoV-2 and HIV. J Med Virol. 2020;92(9):1415. [CrossRef]
  12. Ayerdi O, Puerta T, Clavo P, Vera M, Ballesteros J, Fuentes ME, et al; Sandoval Study Group. Preventive efficacy of tenofovir/emtricitabine against severe acute respiratory syndrome coronavirus 2 among pre-exposure prophylaxis users. Open Forum Infect Dis. 2020;7(11):ofaa455. [CrossRef]
  13. Delaugerre C, Assoumou L, Maylin S. SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine-based PrEP in 2020: a sub-study of PREVENIR-ANRS and SAPRIS-Sero [Abstract]. In: Abstracts of 11th International AIDS Society (IAS) Conference on HIV Science (July 18-21, 2021).
  14. RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345-52. [CrossRef]
  15. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for Covid-19 – Interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497-511. [CrossRef]
  16. Di Castelnuovo A, Costanzo S, Antinori A, Berselli N, Blandi L, Bonaccio M, et al; COVID-19 RISK and Treatments (CORIST) Collaboration. Lopinavir/ritonavir and darunavir/cobicistat in hospitalized COVID-19 patients: findings from the multicenter Italian CORIST Study. Front Med (Lausanne). 2021;8:639970. [CrossRef]
  17. Milic J, Novella A, Meschiari M, Menozzi M, Santoro A, Bedini A, et al. Darunavir/cobicistat is associated with negative outcomes in HIV-negative patients with severe COVID-19 pneumonia. AIDS Res Hum Retroviruses. 2021;37(4):283-91. [CrossRef]
  18. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221-4. [CrossRef]
  19. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281-92.e6. [CrossRef]
  20. Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30(4):343-55. [CrossRef]
  21. Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368(6492):779-82. [CrossRef]
  22. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289-93. [CrossRef]
  23. Sousa SF, Cerqueira NM, Fernandes PA, Ramos MJ. Virtual screening in drug design and development. Comb Chem High Throughput Screen. 2010;13(5):442-53. [CrossRef]
  24. Ibrahim MAA, Abdelrahman AHM, Hegazy MF. In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors. J Biomol Struct Dyn. 2021;39(15):5756-67. [CrossRef]
  25. Absalan A, Doroud D, Salehi-Vaziri M, Kaghazian H, Ahmadi N, Zali F, et al. Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19. Gastroenterol Hepatol Bed Bench. 2020;13(4):355-60.
  26. Nutho B, Mahalapbutr P, Hengphasatporn K, Pattaranggoon NC, Simanon N, Shigeta Y, et al. Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic ınsights into the ınhibitory mechanisms. Biochemistry. 2020;59(18):1769-79. [CrossRef]
  27. Prashantha CN, Gouthami K, Lavanya L, Bhavanam S, Jakhar A, Shakthiraju RG, et al. Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus. J Mol Graph Model. 2021;102:107769. [CrossRef]
  28. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al; EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397-1408. [CrossRef]